Early cancer screening is a real necessity, but commercialization and compliance are the real hurdles.

View Original
CryptoFrontier
Aimeison Resubmits Hong Kong IPO After 10 Years Without Profit
Second Hong Kong IPO Attempt After Prior Filing Lapse

Wuhan Aimeison Life Sciences Co., Ltd., a Chinese early cancer screening company, has resubmitted its prospectus to the Hong Kong Stock Exchange for main board listing, with China Bohai Bank
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin